Multidisciplinary Management of Hepatocellular Carcinoma Innovations in Diagnosis, Treatment, and Prognostication

Dear Colleagues,

The landscape of diagnosis and treatment for hepatocellular carcinoma has dramatically changed over the last few decades, transcending beyond the concept of univocal treatment for a specific tumor stage and advancing the hierarchy of the best therapeutic choices. Emerging evidence supports the notion that hepatologists and oncologists may focus on the role of patients’ characteristics (such as liver function) and comorbidities rather than only on tumor features. Treatment personalization is therefore pivotal and should not only take into account the single case, but should also be founded on a multidisciplinary approach that includes all the professional figures involved in HCC management, such as hepatologists, oncologists, radiologists, and surgeons.

This Special Issue aims to analyze how far the paradigm of HCC management has changed. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the role of liver function in the choice of a treatment for HCC,  the role of patients’ comorbidities in the management of HCC, the role of a multidisciplinary approach in HCC management; indications and contraindications to treatments (surgery, locoregional techniques, or systemic therapies), and the role of prognostic biomarkers that may change the preferred therapeutic choice.

We look forward to receiving your contributions.

Dr. Francesca Romana Ponziani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• MASLD
• hepatocellular carcinoma
• liver transplantation
• systemic therapy
• immune checkpoint inhibitors
• transarterial chemoembolization
• transarterial radioembolization
• therapeutic hierarchy